Refractive and Biometric Outcomes Following a Single Dose Intravitreal Bevacizumab Administration

Purpose: To evaluate the effect of intravitreal bevacizumab monotherapy on refractive and biometric parameters among patients with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO) or clinically significant macular edema (CSME). Patients and Methods: This prospective study included patients aged between 35-50 years who received a single dose intravitreal injection of bevacizumab in Khatam-Al-Anbia eye hospital, Mashhad University of Medical Sciences, Mashhad, Iran, from 2015 to 2017. Dry and cycloplegic refraction, visual function, accommodative amplitude, keratometry results, axial length, anterior chamber depth, lens thickness, vitreous length and central corneal thickness, before and 1 and 3 months after injection were evaluated and compared. Results: Twenty seven patients (fifteen females and twelve males) entered the study with the mean age of 45.18 ± 2.68 years. The mean best corrected visual acuity (BCVA) of patients improved significantly (P = 0.006) three months post injection compared to before injection. No statistically significant difference was observed between the refractive parameters (dry and cycloplegic refraction), accommodative amplitude, biometric parameters including keratometry, axial length, and lens thickness, before and 1 or 3 months after injection. Conclusion: Based on our findings bevacizumab monotherapy improved the mean BCVA among patients with CRVO, BRVO, or CSME, but had no significant effect on refractive and biometric parameters of the treated eyes up to 3 months after injection.